<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273453</url>
  </required_header>
  <id_info>
    <org_study_id>582.2</org_study_id>
    <nct_id>NCT02273453</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets</brief_title>
  <official_title>A Randomised, Double-blind, Double-dummy, Placebo-controlled Cross-over Trial to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets (120 mg Valerian / 80 mg Lemon Balm)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the presence of a hang-over effect in healthy volunteers the day after the
      administration of Songha® Night
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline of the Pupillary Unrest Index (PUI) measured by pupillographic sleepiness test</measure>
    <time_frame>08:00h, 09:30h, 11:00h at Day 7 of each treament period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the Pupillary Unrest Index (PUI) measured by pupillographic sleepiness test</measure>
    <time_frame>up to day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective sleepiness rated on a 7 point scale</measure>
    <time_frame>up to day 36</time_frame>
    <description>Stanford Sleepiness Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective sleepiness measured on a visual analogue scale (VAS)</measure>
    <time_frame>up to day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep quality measured on a visual analogue scale (VAS)</measure>
    <time_frame>up to day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of tolerability by investigator on 4-point scale</measure>
    <time_frame>Day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of tolerability by patient on 4-point scale</measure>
    <time_frame>Day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 36 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Songha® Night</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Oxazepam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Songha® Night</intervention_name>
    <arm_group_label>Songha® Night</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxazepam</intervention_name>
    <arm_group_label>Placebo + Oxazepam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Oxazepam</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female Caucasian subjects aged 20-60 years

          -  Normal outcome in Pittsburgh Sleep Quality Index (PSQI), below mean +2 Standard
             Deviation (SDs)

          -  No manifest sleep disorder diagnosed by polysomnography

          -  Normal pupillary function

          -  Willing and able to give written informed consent in accordance with Good Clinical
             Practice (GCP) and local legislation prior to participation in the study and able to
             perform the study during the full time period of 36 days

        Exclusion Criteria:

          -  Subjective sleep duration of less than 3 hours in the night before the test

          -  Caffeine, nicotine or alcohol on the day (from midnight) of the test

          -  Alcohol consumption on the evening before visits 3, 5 or 7

          -  Eye-drops or other drugs, taken orally or intravenously, influencing pupil size or
             motility

          -  Shift work

          -  Drug and alcohol abuse

          -  Use of psycho-active drugs during the past 30 days

          -  Any treatment that might interfere with the evaluation of the test drug

          -  Any drug known to interact with benzodiazepines and related drugs, e.g.
             antiepileptics, antihistaminics, muscle relaxant drugs, antihypertensive drugs, drugs
             inhibiting cytochrome P450

          -  Any serious disorder that might interfere with his/her participation in this study and
             the evaluation of the efficacy or safety of the test drug (e.g. renal insufficiency,
             hepatic or metabolic dysfunction, cardiovascular disease, psychiatric disorder,
             myasthenia gravis, delirious state, etc.)

          -  Known hypersensitivity to any of the ingredients of the study drugs

          -  Pregnant or nursing women or inadequate birth control methods (this applies to female
             of childbearing potential only)

          -  Participation in another trial within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

